Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: Insights from naive and switch patients.

ABSTRACT: Ofatumumab (OFA), a fully human anti-CD20 monoclonal antibody, has shown promising efficacy in treating relapsing multiple sclerosis (RMS) by depleting B cells and reducing disease activity. This real-world, prospective, multicenter study evaluated the effectiveness and safety of OFA in treatment-naïve patients and those transitioning from other disease-modifying therapies (DMTs), including natalizumab (NTZ). RRMS patients initiating OFA at seven MS centers in Sicily and treated for at least 12 months were analyzed. Outcomes included annualized relapse rates (ARR), Expanded Disability Status Scale (EDSS), and the percentage of patients free from relapse, MRI activity, and confirmed EDSS worsening (CEW). Of 213 patients, 66 (30.9 ​%) were naïve and 147 (69.1 ​%) were switchers. At 12 months

SUBMITTER: Chisari CG 

PROVIDER: S-EPMC12664450 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature